Chapter 5 - Clinical Trial Simulation#
Presenter : HeeSeok Yoo#
Introduction#
Monte Carlo simulation : example of coin toss
General Steps |
Applied to te coin toss example |
---|---|
Specify numerical values for: |
|
- Simulation parameters |
Probability of heads = 0.50 |
- Sample size |
10 tosses of the coin |
- Analysis/test statistics |
Number of heads out of the 10 tosses |
For each replication: |
|
1. Generate data |
Generate 10 random coin tosses |
2. Run Analysis |
Count the number of heads out of 10 tosses |
3. Keep track of the performance |
Keep track of 2 and repeat 1,000 times |
In Clinical trial, we can’t repeat the trial like coin flip.
The Utility of simulation studies in a clinical design prcess has become very important.
Clinical Trial Simulation#
Terms#
Operating characteristics - description of how a design performs under various scenarios.
Scenario - List of values specifying the ‘true’ underlying parameters, such as true response rates, recuritment rate, etc.
Simulation - Repeated analyses of randomly generated datasets drawn under specific assumptions.
Simulation report - Written documents that provides the explanation, details, and justification of the simulation study.
Trial design - Details about how the trial is conducted.
Virtual trial - Clinical trial being simulated in computer.
Overview of Clinical Trial Simulation#
The goal of cilnical trial sumulation is to make virtual trial design match as closely as possible how the trial will be conducted.
General steps of simulation for an adaptive clinical trial would involve: ** Step 1: Simulate the arrival time of the next patient. ** Step 2: Check the stopping rules to see if the trial should be stopped. ** Step 3: If the trial not stopped, enroll more patients into the nexy interim analysis. ** Step 4: Simulate the patient outcome as a fuction of the treatment. ** Step 5: Repeat steps 1-4
Principles of Simulation-Guided Trial Design#
Simulation-guided trial design encourages evaluating multiple design options early to ensure the most efficient and ethical choice is made for each clinical question.
Adaptive designs can improve trial success by anticipating potential regrets and adjusting accordingly, serving as a form of ‘insurance’ against trial failure.
Simulation-Guided Design Planning Case Study#
Simulation studies help explore the trade-offs between trial designs beyond average behavior.
Rather than recommending one design, a Bayesian adaptive approach is used to review different metrics.
Design and Scenario Assumptions#
No. |
Trial designs |
Scenarios |
---|---|---|
1 |
Equal randomisation |
Equal treatment effect/response rate (Null) |
- 1:1 allocation to E and S |
- pS = 0.3 and pE = 0.3 |
|
2 |
RAR with no minimum/maximum allocation |
10% higher response rate in E |
- At interim analysis, adapt the |
- pS = 0.3 and pE = 0.4 |
|
allocation probability for E to |
||
probability that E has higher |
||
response rate than S (pE) |
||
- Allocation of S would be 1 − pE |
||
3 |
RAR with minimum/maximum allocation |
20% higher response rate in E |
- Same as Design 2 with 10% minimum |
- pS = 0.3 and pE = 0.5 |
|
and 90% maximal allocation |
||
probabilities, to ensure that the |
||
allocation does not get ‘stuck’ |
||
on one study arm |
Patient enrollment followed a Poisson process with interim analysis every 10 subjects after a 30-subject burn-in.
Response probabilities:
pS ~ Beta(0.2, 0.8)
pE ~ Beta(0.2, 0.8)
Stopping rules:
Superiority threshold = 0.995
Futility threshold = 0.005
Ensures Type I error < 3.3% under null
Simulation results#
Type I error ~0.03 in Scenario 1 across designs
Design 1 has highest power in all scenarios (0.72 in Scenario 3)
Early stopping rates and mean sample sizes vary
P20 metric introduced: % of trials where ≥20 more patients assigned to SOC
Examination of Singl Virtual Trials#
Figures display randomization probabilities over time for virtual trials
Design 2 shows large imbalance in some trials, e.g., 172:26 (SOC:E) in null scenario
Design 3 mitigates imbalance via min allocation threshold
In Scenario 2 and 3, some trials assigned more to inferior treatment → RAR risk
P20 exposes ethical risk of RAR misallocating patients
Even fixed randomization (Design 1) can show imbalance without blocked randomization
Design evaluation must go beyond averages — include worst-case risks
Simulation Reports#
Essential for adaptive and complex trials
DIA-ADSWG recommends including:
Objectives, inputs, design rules
Scenario definitions, operating characteristics
Discussion and justification of chosen design (Table 5.4)
Simulation Software#
Commercial: EAST®, ADDPLAN®, COMPASS®, FACTS
Advantages: ready-to-use, no coding required
Limitations: cost, limited flexibility for custom designs
Open-source (R-based):
Notable packages:
rpact
,MAMS
,Mediana
,multiarm
,adaptr
,OCTOPUS
,gsDesign
Many offer vignette tutorials
Available on CRAN and GitHub
Conclusion#
Simulation is critical to evaluate trial design operating characteristics
Adaptive designs may improve ethics but carry trade-offs
No universal best design — simulation helps identify the most efficient and ethical option per research question